APRI - Apricus Biosciences, Inc.

YHD - YHD Delayed Price. Currency in USD
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (5Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • Benzinga

    Why Seelos Therapeutics Shares Are Surging Out Of The Gate

    Thinly traded nanocap biotech Seelos Therapeutics Inc (NASDAQ: SEEL) is trading sharply higher on over three times its average volume. Seelos, which develops therapies for central nervous system disorders and other rare conditions, issued an update after the close Thursday on its pipeline development as well as corporate highlights. Since the completion of the reverse merger Jan. 24, Seelos has acquired two candidates: SLS-005 targeting orphan diseases of the CNS; and SLS-007 targeting alpha-synuclein aggregates in Parkinson's disease.

  • GlobeNewswire

    Seelos Therapeutics, Inc. Announces Successful Completion of its Merger with Apricus Biosciences, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders

    Seelos Therapeutics, Inc. (Nasdaq:SEEL), a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders, announced today the completion of its previously disclosed merger with Apricus Biosciences, Inc. The combined company changed its name to Seelos Therapeutics, Inc. and will focus on the development and commercialization of CNS therapeutics with known mechanisms of action in areas with a highly unmet medical need. Seelos is expected to begin trading today, January 24, 2019, on The Nasdaq Capital Market under the ticker symbol “SEEL”. The previous ticker symbol was “APRI” (APRI).  Seelos will maintain its headquarters in New York, New York and will be led by Chairman and Chief Executive Officer, Raj Mehra, Ph.D.